Transplant Patients
- Sirolimus
- Cyclosporine
- Tacrolimus
- Corticosteroids

HIV Patients
- Efavirenz
- Lopinavir
- Ritonavir
- Fosamprenavir

Cancer Patients
- Taxanes
- Vinca Alkaloids
- Irinotecan
- Antinausea agents (5HT3 Antagonists)

Heart Patients
- Amiodarone
- HMG-CoA Reductase Inhibitors (Statins)
- Calcium Channel Blockers
- Digoxin

Key Patient Populations with Potential Posaconazole Drug Interactions

Adapted from references 7, 16, 19, 22, 42.
Posaconazole Regulatory Timeline

2005
- Approval by the EMA
- Approval by the FDA for OPC and IFI

2006
- Approval by the FDA as IV for IFI

2013
- Deferred due date of PREA requirement for IFI

2014
- Deferred due date of PREA requirement for OPC

2018
- Final due date of PREA requirements as DRT and IV

2019

2021

EMA – European Medicines Agency, FDA – Food and Drug Administration, PREA – Pediatric Research Equity Act
Adapted from references 61-66. → 49, 51, 62-65.
Common Uses of Posaconazole

**Prophylaxis**

- Primarily prophylaxis of candidiasis** and aspergillosis**
- SUS - 200mg TID
- IV, DRT – 300mg BID once, then 300mg QD

**Treatment**

- **Aspergillus**
  - Typically used as salvage therapy
  - 200mg QID until patient stabilizes. Then, 400mg BID

- **Candida**
  - Primary treatment*
  - 100mg BID once, then 100mg QD x 13 days
  - 400mg BID

- **Miscellaneous Fungi**
  - Cryptococcus, Mucorales, etc.
  - 200mg QID or 400mg BID

Unless otherwise noted, listed dosages are for the posaconazole oral suspension.

QD – Once daily, BID – Twice daily, TID – Thrice daily, QID – Four times a day
SUS – Suspension, IV- Intravenous solution, DRT – Delayed-release tablet

*Denotes FDA approval for the posaconazole oral suspension
**Denotes FDA approval for all available posaconazole formulations
All other indications shown are off-label uses.
Adapted from references 5, 16, 78, 79